TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30464234
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise intervention (n = 14), three 50‐min sessions weekly from 16 weeks gestation to delivery
Study: 24019047
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) - one Fleet enema on the morning of surgery
Study: 24019047
Drug: Non-mechanical bowel
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-mechanical bowel preparation (non-MBP) - no enema before surgery
Study: 19663521
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg once daily for 1 year
Study: 19663521
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily for 1 year
Study: 10980875
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa receptor blockade
Study: 1446142
Drug: GR32191, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191, 40 mg four times daily for 3 weeks
Study: 6152435
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.075 U/kg body weight)
Study: 6152435
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (0.075 U/kg body weight)
Study: 6152435
Drug: Bovine insulin
Normalized name: Bovine insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine insulin (0.075 U/kg body weight)
Study: 30997499
Drug: Sucrose (1.25-1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (1.25-1.75 L of beverage sweetened with sucrose daily for 12 weeks)
Study: 30997499
Drug: Saccharin (1.25-1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharin (1.25-1.75 L of beverage sweetened with saccharin daily for 12 weeks)
Study: 30997499
Drug: Sucralose (1.25-1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (1.25-1.75 L of beverage sweetened with sucralose daily for 12 weeks)
Study: 30997499
Drug: Aspartame (1.25-1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (1.25-1.75 L of beverage sweetened with aspartame daily for 12 weeks)
Study: 30997499
Drug: Rebaudioside A
Normalized name: Rebaudioside A
DrugBank: Rebaudioside A (DB15136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebaudioside A (1.25-1.75 L of beverage sweetened with rebA daily for 12 weeks)
Study: 20649060
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate with potassium salt (GS‐K) 1500 mg daily
Study: 20649060
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate with sodium salt (GS‐Na) 1500 mg daily
Study: 18379501
Drug: Semax (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semax (1% solution)
Study: 12384844
Drug: Nevirapine (Nvp),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (Nvp), stavudine (d4T), and indinavir (Idv; 1000 mg 3 times daily)
Study: 12384844
Drug: Lamivudine (3TC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (3TC), stavudine (d4T), and indinavir (Idv; 800 mg 3 times daily)
Study: 1809720
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser treatment (GAAS pulsed laser)
Study: 6853932
Drug: Cortisol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (8 mg/kg)
Study: 28902034
Drug: 1,060-nm diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,060-nm diode laser treatment
Study: 24004891
Drug: Orange-fleshed sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange-fleshed sweet potatoes (12 mg β-carotene/d)
Study: 24004891
Drug: Tangerines (5.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangerines (5.3 mg β-cryptoxanthin/d)
Study: 24004891
Drug: White-fleshed sweet
Normalized name: white sweet clover pollen extract
DrugBank: Melilotus albus pollen (DB10858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White-fleshed sweet potatoes with a vitamin A supplement (0.5 mg/d)
Study: 20189491
Drug: MenACWY-CRM administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM administered concomitantly with Tdap and HPV vaccines
Study: 20189491
Drug: MenACWY-CRM administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM administered sequentially with Tdap and HPV vaccines
Study: 16981000
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion of CsA 3 mg/kg/day
Study: 16981000
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of CsA 3 mg/kg/day
Study: 15239026
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg pre-meal 3 x/day) + Metformin (2550 mg/day)
Study: 10908008
Drug: Research conducted
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research conducted in community treatment organizations
Study: 8446968
Drug: Aspirin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (two doses)
Study: 3543037
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of cefamandole (at induction of anesthesia and after 4 and 10 hours)
Study: 3543037
Drug: 8 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 injections of cefamandole (at induction of anesthesia, after 4 hours, then every 6 hours up to 40 hours)
Study: 25515692
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of PSE in the morning (AM(PSE))
Study: 25515692
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of PSE in the afternoon (PM(PSE))
Study: 25515692
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of PSE
Study: 16340195
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir (ACV) ointment
Study: 16340195
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (VACV)
Study: 15134308
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m2/day
Study: 15134308
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg GH/m2/day
Study: 11561869
Drug: Enzyme treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme treatment (trypsin, chymotrypsin, and papain)
Study: 9051139
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 micrograms/kg) plus steroids (500 mg of methylprednisolone or 8 mg of dexamethasone)
Study: 3511184
Drug: Bilateral oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral oophorectomy (crossover treatment)
Study: 3511184
Drug: Tamoxifen (crossover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (crossover treatment)
Study: 3511184
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to progression (initial treatment)
Study: 29882738
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) with a wavelength of 660 nm, 30 mW power, continuous mode emission, 6 J/cm2 dosimetry, applied every 48 hours for 4 weeks.
Study: 24576068
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of sulphadoxine-pyrimethamine (SP3)
Study: 24576068
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of sulphadoxine-pyrimethamine (SP2)
Study: 18603751
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment with standard pulmonary artery catheter
Study: 30950698
Drug: Stretch‐and‐flow voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretch‐and‐flow voice therapy (SnF)
Study: 30950698
Drug: Resonant voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonant voice therapy (RVT)
Study: 16919161
Drug: SFC (50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (50/100 mcg)
Study: 16919161
Drug: FBC (4.5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBC (4.5/160 mcg)
Study: 11350283
Drug: Low molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular-weight heparin
Study: 3428842
Drug: Methyclothiazide 2
Normalized name: methyclothiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide 2 mg alone
Study: 3428842
Drug: Methyclothiazide 2
Normalized name: methyclothiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide 2 mg with triamterene 25 mg
Study: 3428842
Drug: Methyclothiazide 2
Normalized name: methyclothiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide 2 mg with larger doses of triamterene
Study: 25814467
Drug: PEG‐IFN‐α treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐α treatment
Study: 23376601
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for treating child emotional and behavioral symptoms following trauma
Study: 12821205
Drug: Transfer at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer at 30 mg methadone
Study: 12821205
Drug: Transfer when
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer when 'uncomfortable' dosing protocol
Study: 12821205
Drug: Transfer from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer from doses less than 30 mg methadone
Study: 12821205
Drug: Buprenorphine induction
Normalized name: buprenorphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine induction (first dose 4 mg)
Study: 12845731
Drug: Aprotinin (1,000,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1,000,000 KIU by vein injection and 2,000,000 KIU as a bolus in prime)
Study: 7640544
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal nicotine patches
Study: 2565314
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, 25 mg daily for 25 days with 5 days' rest each month
Study: 2565314
Drug: Ascorbic acid,
Normalized name: ASCORBIC ACID, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbic acid, 500 mg daily
Study: 26197451
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of AZD9056 administered orally as a tablet once daily for 28 days
Study: 25607793
Drug: Skin barrier
Normalized name: Skin Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin barrier emulsion cream
Study: 11934964
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate 1500 mg daily for 6 months
Study: 7151087
Drug: Tiapamil (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (1.1 mg/kg)
Study: 7151087
Drug: Tiapamil (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (1.6 mg/kg)
Study: 7151087
Drug: Verapamil (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.07 mg/kg)
Study: 7151087
Drug: Verapamil (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.14 mg/kg)
Study: 28376899
Drug: Oats consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oats consumption (70 g of oats twice a day for 4 weeks)
Study: 15942151
Drug: Chlindamycine phosphate
Normalized name: Clindamycin Phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlindamycine phosphate cream (placebo)
Study: 12598351
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 60 mg/m2 alone
Study: 12598351
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 60 mg/m2 and Cisplatin (CDDP) 50 mg/m2 every 4 weeks
Study: 9890307
Drug: 0.025 to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 to 0.2 mg/h nitroglycerin patch
Study: 2981827
Drug: Chlorpromazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (50 mg injections)
Study: 2981827
Drug: Meperidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (50 mg injections)
Study: 29902939
Drug: Twice-daily early
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily early therapeutic mobility (ETM)
Study: 29902939
Drug: Once-daily early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily early therapeutic mobility (ETM)
Study: 23759286
Drug: Enhanced cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive-behavioral therapy including a virtual reality protocol (ECT)
Study: 23759286
Drug: Inpatient multimodal
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient multimodal treatment (IP)
Study: 6381101
Drug: Hydrotubation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotubation with lactated Ringer's solution
Study: 25037139
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg twice a day and cobimetinib 60 mg once a day 21/7
Study: 25037139
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg twice a day and cobimetinib 80 mg once a day 14/14
Study: 25037139
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg twice a day and cobimetinib 60 mg 28/0
Study: 25037139
Drug: vemurafenib and
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib and cobimetinib (various dosing regimens)
Study: 10214832
Drug: Dydrogesterone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (2.5 mg, 5 mg, 10 mg, 15 mg) combined with 2 mg of micronized 17beta-estradiol
Study: 7605019
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at concentrations of 1, 3, 10, 30, and 100 ppm
Study: 87965
Drug: T3 20
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 20 micrograms four times daily from surgery through the twelfth postoperative month
Study: 87965
Drug: T3 20
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 20 micrograms four times daily
Study: 30939507
Drug: TXA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (15 mg/kg IV before incision and a second identical dose 3 hours after the initial dose)
Study: 28357822
Drug: Baxter elastomeric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baxter elastomeric LV10 InfusorTM pump using ceftazidime 6 g under 203 kPa
Study: 28357822
Drug: Baxter elastomeric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baxter elastomeric LV10 InfusorTM pump using ucloxacillin 8 g
Study: 21480103
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d., Bismuth subcitrate 240 mg b.i.d. for two weeks
Study: 21480103
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d., Furazolidone 200 mg b.i.d., Omeprazole 20 mg b.i.d. (without Bismuth)
Study: 17146320
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (18 mug)
Study: 9167112
Drug: Extended-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release glipizide
Study: 8467322
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose insulin infusion (5 mU/m2/min) during clamp A
Study: 8467322
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin infusion (60 mU/m2/min) during clamp B
Study: 8467322
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy (50 mg atenolol + 30 mg furosemide per day) prior to each clamp
Study: 2431015
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% dermal cream
Study: 20420270
Drug: Increased progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased progesterone dosage
Study: 20420270
Drug: Standard progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard progesterone dosage (Control)
Study: 18488134
Drug: Web-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based administration of PFDI-20
Study: 18488134
Drug: Web-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based administration of PFIQ-7
Study: 15596631
Drug: Survey administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey administered to participants regarding attitudes, beliefs, and practices about ACP
Study: 3300171
Drug: Citalopram (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30-60 mg daily for at least 3 weeks)
Study: 3300171
Drug: Amitriptyline (75-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75-225 mg daily for at least 3 weeks)
Study: 30166290
Drug: 6-month self-rehabilitation
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month self-rehabilitation programme in addition to botulinum toxin injections (BTIs) and conventional physiotherapy
Study: 30166290
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (BTIs) alone and conventional physiotherapy
Study: 14695501
Drug: Tetracaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 4% gel (1.0 g)
Study: 14695501
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (1.0 g of eucerin-plus cream)
Study: 11056593
Drug: rhNGF, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF, 0.1 microg/kg, subcutaneous injection 3 times per week for 48 weeks
Study: 11056593
Drug: Placebo, subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneous injection 3 times per week for 48 weeks
Study: 8831327
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg and Sch 1.5 mg/kg (Group I)
Study: 8831327
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg and Sch 1.5 mg/kg (Group II)
Study: 8831327
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg, alfentanil 40 micrograms/kg, and Sch 1.5 mg/kg (Group III)
Study: 1336347
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 g) and tazobactam (500 mg) every 8 h
Study: 1336347
Drug: Imipenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (500 mg) and cilastatin (500 mg) every 8 h
Study: 31494097
Drug: AMG 714
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 714 (8 mg/kg, 7 intravenous doses over 10 weeks)
Study: 27542322
Drug: Elbasvir/grazoprevir (EBR/GZR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (EBR/GZR) 50mg/100mg once daily for 12 weeks (n=129)
Study: 27542322
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) 400mg once daily plus pegylated interferon/ribavirin (PR) for 12 weeks (n=128)
Study: 15142328
Drug: Repetitive short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive short VMs after Echovist‐300 injection
Study: 15142328
Drug: Repetitive short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive short VMs after agitated saline injection
Study: 11206674
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg once daily for 16 weeks
Study: 11206674
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily for 16 weeks
Study: 9534010
Drug: Benfluorex (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (3 tablets daily)
Study: 7831993
Drug: Lower neuroleptic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower neuroleptic doses in the suicide group
Study: 3049861
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied ophthalmic solution containing trimethoprim and polymyxin B (TP)
Study: 3049861
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied ophthalmic solution containing trimethoprim, polymyxin B, and sulfacetamide
Study: 29334997
Drug: Weekly self-monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Study: 29334997
Drug: Monthly self-monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly self-monitoring of blood glucose (4-point glucose measurements before meals and bedtime)
Study: 25023711
Drug: CT-guided nucleoplasty
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided nucleoplasty with nerve root injection
Study: 25023711
Drug: CT-guided transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided transforaminal lumbar epidural injections